Antibacterial Nanoparticles Therapeutic (ANT) Study
Closed Special Notice Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- PANDHA-26-P-0000_036893
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541713 Research and Development in Nanotechnology
- Place of performance
- Silver Spring, Maryland 20910, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency (DHA) has published a Notice of Intent to Sole Source a research contract to the University of Notre Dame for the Antibacterial Nanoparticles Therapeutic (ANT) Study. The special notice was posted on April 14, 2026, and announces DHA's intention to award a sole source contract to conduct research on innovative antibacterial nanoparticles with phage-mimicking properties (PhANPs). The research will focus on testing these nanoparticles against multi-drug resistant (MDR) strains of Pseudomonas aeruginosa, a bacterial pathogen responsible for severe infections in service members following battlefield injuries. The University of Notre Dame holds the patent for this unique technology, which was awarded in 2024 under patent number US-12161725-B2. This sole source procurement is intended to advance combat medicine and contribute to FDA approval of a novel therapeutic for treating difficult-to-manage bacterial infections.
Interested parties have until 2:00 p.m. Eastern Time on April 28, 2026, to submit capability information demonstrating their ability to provide the stated capability to either Ms. Linda Hinson or Mr. Sharew Hailu at the Defense Health Agency Contracting Activity. The primary objective of this research initiative is to develop novel therapeutics that will reduce morbidity and mortality rates among service members, enhance operational readiness, and advance combat medical capabilities while contributing to broader biosecurity and civilian health initiatives. The Government will evaluate all responses received by the deadline; however, DHA retains sole discretion to proceed with sole source negotiations, open the procurement to competition, or award directly to the University of Notre Dame if no alternative responses are submitted. This opportunity falls under nanotechnology research and development (NAICS 541713) and health research and development services (PSC AN13), with no small business or other set-asides applied to this procurement.
Notice text
The University of Notre Dame will conduct a study to test innovative antibacterial nanoparticles with phage-mimicking properties (PhANPs) against combat relevant multi-drug resistant (MDR) strains of Pseudomonas (P.) aeruginosa, bacterial pathogen to cause hard to treat and even deadly infections in service members after battlefield injuries. There is a need to bring novel therapeutics to the military health care to treat MDR P. aeruginosa. The collaborative partner of this study is the University of Notre Dame, the patent owner of a unique technology (phage-mimicking nanoparticles) that provides life-saving therapeutics for service members and civilians. This technology was awarded a patent in 2024 - US-12161725-B2. Government anticipates that the collaborative efforts will contribute to Food and Drug Administration (FDA) approval of this innovative therapy, leading to reduced morbidity and mortality rates, enhanced operational readiness, advanced combat medicine, and substantial contributions to broader biosecurity initiatives and civilian health improvements.
Files
| File | Type | Posted |
|---|---|---|
| B01. Notice of Intent to Sole Source PANDHA-26-P-0000 036893.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Antibacterial Nanoparticles Therapeutic (ANT) Study | Award Notice | |
| This notice | Special Notice | |
| Antibacterial Nanoparticles Therapeutic (ANT) Study | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| NOTICE OF INTENT TO SOLE SOURCE for the Development of a Handheld Device for Rapid Assessment of Burn Sepsis Risk | — | No set-aside | |
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity